Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia-Reference-Cited by-同舟云学术

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Published:2018-09-10 Issue:4 Volume:33 Page:905-917
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Moujalled Donia M.,Pomilio Giovanna,Ghiurau Corina,Ivey Adam,Salmon Jessica,Rijal Sewa,Macraild Sarah,Zhang Lan,Teh Tse-Chieh,Tiong Ing-Soo,Lan Ping,Chanrion Maia,Claperon Audrey,Rocchetti Francesca,Zichi Adrien,Kraus-Berthier Laurence,Wang Youzhen,Halilovic Ensar,Morris Erick,Colland Frédéric,Segal David,Huang David,Roberts Andrew W.^ORCID,Maragno Ana Leticia,Lessene Guillaume,Geneste Olivier,Wei Andrew H.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0261-3.pdf

Reference40 articles.

1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. New Engl J Med. 2016;374:2209–21.

2. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–10.

3. Wei AH, Tiong S. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogomycin and venetoclax bring new hope to AML. Blood. 2017;130:2469–74. blood-2017-2008-784066

4. Vo T-T, Ryan J, Carrasco R, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell . 2012;151:344–55.

5. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. New Engl J Med. 2015;374:311–22.

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway;PLOS ONE;2024-07-25

2. Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status;Blood Advances;2024-06-28

3. BCL-2 inhibition in haematological malignancies: Clinical application and complications;Blood Reviews;2024-05

4. Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax;Pharmaceutics;2024-01-31

5. Venetoclax resistance in acute myeloid leukaemia—Clinical and biological insights;British Journal of Haematology;2024-01-31